Bausch Health is executing operationally, but the RED-C setback and the looming IRA/patent cliffs turn 2026–2028 into a race between cash flow and a $6B maturity wall—likely requiring BLCO monetization to survive.
Overview
After FY2025 and into Q1’26, Bausch Health shows tangible operational momentum—FY2025 revenue of $10.266B (+7% reported; +5% organic) and Q1’26 revenue of $2.524B (+12% reported). Segmentally, Salix grew 18% (with Xifaxan +21%), Solta grew 51% reported (+19% organic post-Shibo), and BLCO grew 9% reported while raising FY2026 guidance. However, the enterprise is constrained by a highly leveraged capital structure ($21.6B debt; ~5.7x net leverage) and a narrowing window before Xifaxan faces IRA pricing pressure (2027) and generic entry (settlements in 2028; HE patents to 2029). RED-C’s Phase 3 failure eliminated a key successor opportunity and drove a $1.426B impairment, underscoring that balance sheet strategy—not just operations—will determine equity outcomes into 2027–2028.